(New York, N.Y. – April 24, 2014)Uniting Against Lung Cancer (UALC), a nonprofit dedicated to funding innovative research and raising awareness for lung cancer, announces that it has achieved a new level of funding this year, committing more than $1.5 million in lung cancer research grants to premier medical and research institutions across the country.  This contribution brings UALC’s total funding for lung cancer research grants to a total of $11.5 million.

Lung cancer is the nation’s deadliest cancer, responsible for over 220,000 new diagnoses and nearly 160,000 cancer deaths each year. With the support of its partners across the country, UALC funds the critical research that will improve treatment options, extend survival, and find a cure for lung cancer patients. These efforts have led to more than $55 million in continued support from federal and public sources, new therapies in clinical trials, and major advances improving treatment for thousands of lung cancer patients.

Recipients of funding are selected by the UALC Medical Committee, comprised of the top physicians and scientists in the field. This year’s grantees are developing new methods for early detection of lung cancer; investigating new targets and novel therapies for both small cell and non small cell lung cancer; and gaining a greater understanding of the origins of lung cancer to find a cure for the nation’s leading cancer killer.

New funding opportunities will be open to applicants in May, 2014. Visit http://www.unitingagainstlungcancer.org/research for more details.

Recipients of UALC funding are:

Collin Blakely, MD, PhD

University of California, San Francisco

Evolution and impact of tumor molecular heterogeneity on response to EGFR-targeted lung cancer therapy

Sponsored by Uniting Against Lung Cancer and Free to Breathe

Emily Cheng, MD, PhD

Memorial Sloan-Kettering Cancer Center

Targeting the BCL-2 Family in Small Cell Lung Cancer

Sponsored by The Judy & Fred Wilpon Foundation and Tishman Speyer

William Cheung, PhD

Yale University

Treating metastasis by differentiation therapy: Identifying druggable pathways

Sponsored by The Tom Zangas Lung Cancer Foundation and the Mike Pascucci Lung Cancer Association

Curtis Chong, MD, PhD

Dana-Farber Cancer Institute

Combination screening of targeted therapies as a strategy to understand and overcome resistance to EGFR inhibitors in lung cancer patients

Sponsored by the Marjorie M. Fisher Fund, the Tighe-Hidalgo Foundation, and the Office of Dr. David Hidalgo

Subhajyoti De, PhD

University of Colorado, Denver

Identifying potential driver mutations in gene promoters in a cohort of completely sequenced NSCLC genomes

Sponsored by Elliot's Legacy and Joan's Legacy

Anna Farago, MD, PhD

Massachusetts General Hospital Cancer Center

Leveraging genetically engineered preclinical models of small cell lung cancer for advanced therapeutic studies

Sponsored by Elliot's Legacy and Joan's Legacy

Christine Fillmore, PhD

Children’s Hospital Boston

Epigenetic inhibitors in personalized therapy for Brg1 and EGFR mutant lung tumors

Sponsored by Joan’s Legacy in honor of Meryl Bralower

Zeynep Gumus, PhD

Weill Cornell Medical College

Identification of Constitutional Risk Genes for Non-Small Cell Lung Cancer Adenocarcinoma

Sponsored by The Ira Waldbaum Family Foundation and The Malinsky Family Charitable Trust

Sandra Hofmann, PhD

University of Texas Southwestern Medical Center

DHHC Protein Palmitoyltransferases in Small Cell Lung Cancer

Sponsored by Elliot's Legacy and Joan's Legacy

Matthew Niederst, PhD

Massachusetts General Hospital Cancer Center

Determining the mechanisms of intrinsic and acquired resistance to the 3rd generation EGFR inhibitor CO-1686

Sponsored by Pershing Square Capital Management and Joan's Legacy

Ann Marie Pendergast, PhD

Duke University Medical Center

Novel druggable pathway required for lung cancer progression and metastasis

Sponsored by The Hank Thompson Fund, Lily’s Light, and the Caine Halter Fund for Lung Cancer Research

David Shackelford, MD, PhD

University of California, Los Angeles

Targeting LKB1-deficient non-small cell lung cancer through the NRF2 pathway

Sponsored by Greenlight Capital and The Durst Organization

Takeshi Shimamura, PhD

Loyola University Chicago

BET bromodomain inhibitor resistance in LKB1 deficient mutant KRAS NSCLC

Sponsored by Chicago Lung Run

Ferdinandos Skoulidis, MD, PhD

MD Anderson Cancer Center

Impact of NF1 inactivation on the pathogenesis, signaling circuitry and therapeutic responsiveness of NSCLC in a novel co-clinical trial of targeted therapy

Sponsored by Elliot's Legacy and Joan's Legacy

Alison Taylor, PhD

Dana-Farber Cancer Institute

Chromosomal Gains in Lung Squamous Carcinoma

Sponsored by the Nancy Raisman Memorial Fund

To see a complete description of the funded projects and to learn more about supporting UALC Scientific Programs, visit http://www.unitingagainstlungcancer.org/research

About Uniting Against Lung Cancer

Uniting Against Lung Cancer is dedicated to funding innovative research that enables patients, smokers and non-smokers alike, to win their battles with lung cancer and live healthy, cancer-free lives years after diagnosis. UALC and its Partners across the country raise awareness and critical funds for lung cancer research. For more information, please visit www.UnitingAgainstLungCancer.org.